A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects with Advanced Malignancies
Study of Drug PLX2853 in Subjects with Advanced Cancer
Sponsor: Plexxikon Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR7748
U.S. Govt. ID: NCT03297424
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the highest dose of the study drug that can be given safely to people with certain cancers. The study will also look at how effective the study drug is in treating certain cancers. The study drug is PLX2853. The participants in this study will be the first people to receive PLX2853.
This study is closed
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have a confirmed solid tumor? (Example: ovarian cancer, lung cancer, skin cancer) Yes No
Have you had treatment for your disease in the past? Or, does a standard therapy not exist for your disease? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE